DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2810-2816

  Pan, Xiao Su ^a   Fisher, L Mark ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG MECHANISM; DRUG POTENCY; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STREPTOCOCCUS PNEUMONIAE;

EID: 0031784975     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2810     Document Type: Article

References (43)

1. Adams, D. E., E. M. Shekhtman, E. L. Zechiedrich, M. B. Schmid, and N. R. Cozzarelli. 1992. The role of topoisomerase IV in partitioning DNA replicons and the structure of catenated intermediates in DNA replication. Cell 71:277-288.
2. Baranova, N. N., and A. A. Neyfakh. 1997. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1396-1398.
3. Bartlett, J. G., and L. M. Grundy. 1995. Community-acquired pneumonia. N. Engl. J. Med. 333:1618-1624.
4. Berger, J. M., S. J. Gamblin, S. C. Harrison, and J. C. Wang. 1996. Structure and mechanism of DNA topoisomerase IV. Nature (London) 379:225-232.
5. Cullen, M. E., A. W. Wyke, R. Kuroda, and L. M. Fisher. 1989. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob. Agents Chemother. 33:886-894.
6. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
7. Ferrero, L., B. Cameron, B. Manse, D. Lagneux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target for quinolones. Mol. Microbiol. 13:641-653.
8. Fournier, B., and D. C. Hooper. 1998. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42:121-128.
9. Gellert, M., K. Mizuuchi, M. H. O'Dea, T. Itoh, and J.-I. Tomizawa. 1977. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc. Natl. Acad. Sci. USA 74:4772-4776.
10. Gellert, M., K. Mizuuchi, M. H. O'Dea, and H. A. Nash. 1976. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. USA 73:3872-3876.
11. Gensberg, K., Y. F. Jin, and L. J. V. Piddock. 1995. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium. FEMS Microbiol. Lett. 132:57-60.
12. Gootz, T. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
13. Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40:879-885.
14. Hofmann, J., M. S. Cetron, M. M. Farley, W. S. Baughman, R. R. Facklam, J. A. Elliott, K. A. Deaver, and R. F. Breiman. 1995. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N. Engl. J. Med. 333: 481-486.
15. Janoir, C., V. Keller, M.-D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
16. Kaatz, G. W., and S. M. Seo. 1995. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39: 2650-2655.
17. Kato, J., Y. Nishimura, R. Imamura, H. Niki, S. Higara, and H. Suzuki. 1990. New topoisomerase essential for chromosomal segregation in E. coli. Cell 63:393-404.
18. Kucers, A., S. M. Crowe, M. L. Grayson, and J. F. Hay (ed.). 1997. The use of antibiotics. A clinical review of antibacterial, antifungal and antiviral drugs, 5th ed., p. 1169-1171. Butterworth-Heinemann, Oxford, England.
19. Mizuuchi, K., L. M. Fisher, M. H. O'Dea, and M. Gellert. 1980. DNA gyrase action involves the introduction of transient double strand breaks into DNA. Proc. Natl. Acad. Sci. USA 77:1847-1851.
20. Morais-Cabral, J. H., A. P. Jackson, C. V. Smith, N. Shikotra, A. Maxwell, and R. C. Liddington. 1997. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388:903-906.
21. Munoz, R., and A. de la Campa. 1996. ParC subunit of DNA topoisomerase IV ot Streptococcus pneumoniae is a primary target of quinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
22. Nakamura, S. 1997. Mechanisms of quinolone resistance. J. Infect. Chemother. 3:128-138.
23. 22a. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial testing; eighth informational supplement. NCCLS document M100-S8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1994. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38:1345-1355.
25. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
26. Pallares, R., J. Linares, M. Vadillo, C. Carbellos, F. Manresa, P. F. Viladrich, R. Martin, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
27. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
28. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
29. Pan, X.-S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
30. Patel, S., A. U. Sprung, B. A. Keller, V. J. Heaton, and L. M. Fisher. 1997. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. Mol. Pharmacol. 52:658-666.
31. Perichon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1166-1167.
32. Randinitis, E. J. 1998. Personal communication.
33. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
34. Tankovic J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in the gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2502-2510.
35. Tomasz, A. 1995. The pneumococcus at the gates. N. Engl. J. Med. 333:314-315.
36. Wang, J. C. 1996. DNA topoisomerases. Annu. Rev. Biochem. 65:635-692.
37. Wasserman, R. A., and J. C. Wang, 1994. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res. 54:1795-1800.
38. Willmott, C. J., and A. Maxwell. 1993. A point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob. Agents Chemother. 37:126-127.
39. Yamada, H., S. Kurose-Hamada, Y. Fukuda, J. Mitsuyama, M. Takahata, S. Minami, Y. Watanabe, and H. Narita. 1997. Quinolone susceptibility of norA-disrupted Staphylococcus aureus. Antimicrob. Agents Chemother. 41: 2308-2309.
40. Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272.
41. Yoshida, H., M. Bogaki, M. Nakamura, L. M. Yamanaka, and S. Nakamura. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35:1647-1650.
42. Zechiedrich, E. L., and N. R. Cozzarelli. 1995. Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli. Genes Dev. 9:2859-2869.
43. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl. Acad. Sci. USA 94:13991-13996.